SCHEMBL4429197

SCHEMBL4429197

O=C1C=CC=C(C2=CN(CCN3CCC(c4ccccc4C(=O)NCc4cccs4)CC3)C=CO2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
PYGM P11217 2/20 0.37
ALDH1A1 P00352 4/20 0.36
LMNA P02545 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
GALR3 O60755 1/20 0.36
POLB P06746 4/20 0.35
HTT P42858 1/20 0.35
HRH2 P25021 1/20 0.34
RAB9A P51151 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PKM P14618 1/20 0.34
UTS2R Q9UKP6 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4884906 0.93 ADAM17 (0.36) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL4880934 0.89 UTS2R (0.38) KMT2AMEN1ALDH1A1POLBUTS2R
SCHEMBL4440061 0.88 MAPK1 (0.36) LMNASMN1; SMN2POLBUTS2RMAPT
SCHEMBL4432447 0.87 PIK3CA (0.37) HPGDKMT2AMEN1ALDH1A1LMNA
SCHEMBL4891155 0.87 UTS2R (0.36) KMT2AMEN1UTS2R
SCHEMBL4438087 0.87 UTS2R (0.43) UTS2R
SCHEMBL4440078 0.86 UTS2R (0.36) UTS2R
SCHEMBL4890309 0.86 BCL3 (0.35) KMT2AMEN1UTS2R
SCHEMBL4433580 0.85 HDAC3 (0.36) HPGDKMT2AMEN1ALDH1A1POLB
SCHEMBL4885280 0.85 STAT3 (0.37) HPGDKMT2AMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759342-B2 Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US claimed
EP-2049120-A1 UROTENSIN II RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2009-04-22 EP claimed
US-20080039454-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-14 US claimed
WO-2008016534-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-02-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039454-A1 Urotensin II receptor antagonists UTS2R, PLAUR, NTSR2 HPGD 1252/4885KMT2A 3204/4885MEN1 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.